Abstract: Disclosed are stabilized dry chemical (e.g. pharmaceutical) compositions containing the water soluble acid addition salt of a poorly soluble basic compound (e.g. mianserin, apomorphine, chlorpromazine, imipramine, or promethazine); an excipient selected from the group consisting of microcrystalline cellulose, lactose, calcium hydrogen phosphate, and mixtures thereof; and a water soluble (>2 mg/ml) alkaline stabilizer. The resulting dry composition are relatively more bioavailable and stable than compositions not containing the water soluble alkaline stabilizer, especially after high temperature (>45.degree.) granulation processes. The process for preparing the dry composition is also more "rugged" with the added water soluble alkaline stabilizer.

Abstract: A para-aramide dope of low degree of polymerization exhibiting an optical anisotropy containing 4-10% by weight of a para-aramide having an inherent viscosity of 1.0-2.5 dl/g and 2-10% by weight of an alkali metal chloride or an alkaline earth metal chloride in a polar amide solvent;a para-aramide fiber obtained by spinning the above-mentioned para-aramide dope of low degree of polymerization;a para-aramide pulp obtained by cutting the above-mentioned para-aramide fiber into a short fiber, mechanically fibrillating the short fiber with a high shearing force and thereafter drying the fibrillated short fiber;a process for producing a para-aramide fiber which comprises adding 0.94-0.99 mole of a para-oriented aromatic dicarboxylic acid halide to 1.00 mole of a para-oriented aromatic diamine in a polar amide solvent in which 2-10% by weight of an alkali metal chloride or an alkaline earth metal chloride is dissolved, carrying out a polymerization at a temperature of -20.degree. C. to 50.degree. C.

Abstract: A waterproof foot covering such as a shoe, boot or the like has a molded-on (foamed-on) outersole and an upper that is lined with a waterproof but water vapor-permeable layer. The lower welt region of the upper is connected to the lower welt region of the waterproof layer and to the outer welt region of the inner sole via an upper band, a lower band, and a multiplicity of tensile-load-resistant straps connecting the upper and lower bands to one another. The lower welt region of the upper is stitched to the upper band. The lower welt region of the waterproof layer and the outer welt region of the inner sole are stitched to the lower band. The straps and the lower band are embedded in the material forming the outersole. This material is connected, in this embedding region, to the waterproof layer in a waterproof manner by molding-on (foaming-on).

Abstract: A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.

Abstract: The method for manufacturing dibenzylamine by reacting benzaldehyde and ammonia in the presence of hydrogen and a hydrogenation catalyst in an inert organic solvent is characterized by the fact that the reaction is conducted with an ammonia ratio of >0.5 mol per mol benzaldehyde and with a hydrogenation catalyst containing a platinum metal and/or a ferrous metal on a carrier. The method is performed at low temperatures, preferably 40.degree.-90.degree. C. In particular, a high selectivity for dibenzylamine of more than 90% is achieved with practically complete benzaldehyde conversion.

Abstract: The invention concerns a phenoxyphenyl compound having the formula ##STR1## wherein R is one or two halogen atoms; andA is CH.sub.2 NR.sub.1 R.sub.2 or 4,5-dihydro-1H-imidazole, in which R.sub.1 and R.sub.2 are independently selected from hydrogen and lower alkyl; ora pharmaceutically acceptable salt thereof.The compounds have long half-lives and can be used against depression.

Abstract: The present invention relates to peptides immunochemically reactive with antibodies to the Epstein-Barr virus (EBV), comprising at least part of the VCA-p18 or VCA-p40 protein, encoded within the EBV open reading frames BFRF3 and BdRF1 respectively, or a functional variant thereof. The invention further relates to nucleic acid sequences encoding these peptides, monoclonal antibodies against these peptides, cell lines capable of producing monoclonal antibodies and anti-idiotype antibodies. The invention also relates to recombinant vector molecules comprising a nucleic acid sequence according to the invention and host cells transformed or transfected with these vector molecules. The invention is further concerned with immunological reagents and methods for the detection of EBV or anti-EBV antibodies and a method for the amplification and detection of Epstein Barr viral nucleic acid.

Abstract: In laminates composed of a woven or knitted fabric and a film impermeable to water and permeable to water vapor, the woven or knitted fabric is made of unstretched or partially stretched fibers. The laminates are highly extensible and retain the shape obtained by stretching. They are particularly useful as starting materials for intermediate layers in shoes and gloves and confer advantages over and above known laminates in respect to the manufacture and properties of the finished articles.

Abstract: Monoquaternary 2,16-bispiperidinylandrostane neuromuscular blocking derivatives having the formula: ##STR1## wherein R.sub.1 is ethyl;R.sub.2 is methyl or allyl; andX.sup.- is a pharmaceutically acceptable anion; or pharmaceutically acceptable salts thereof.

Abstract: A contraceptive method and regimen utilizing an initially greater amount of progestogen, which gradually tapers over the period in which the contraceptive is administered. The regimen includes a multiphasic combination and contraceptive kit containing at least 21 daily sequential dosage units divided into 3 phases. The first phase contains 6-8 dosage units, each containing a progestogen at a dosage equivalent in progestogenic activity to 75-150 .mu.g desogestrel and an estrogen at a dosage equivalent in estrogenic activity to 20-25 .mu.g ethinyl estradiol. The second phase contains 6-8 dosage units, each containing less progestogen than in the previous dosage units, but still having progestogen equivalent to 75-125 .mu.g desogestrel and an estrogen equivalent to 20 .mu.g ethinyl estradiol. The third phase contains 6-8 dosage units, each containing less progestogen than in the previous dosage units, but still containing a progestogen equivalent to 75-100 g desogestrel and an estrogen equivalent to 20 .mu.

Abstract: The invention is related to a 21-chloro-pregnane derivative of the formula ##STR1## or pharmaceutically acceptable salts thereof. The compound has intravenous anaesthetic activity, short onset time and high potency.

Abstract: A method for preparing a thromboplastin reagent from cultured human cells comprising the steps of washing the cells with isotonic aqueous salt solution, lysing the cells by hypotonic shock, and resuspending the cell lysate in a diluent compatible with a one-stage prothrombin time determination to reach a concentration of about 0.5 to 3.0 mg/mL thromboplastin, whereby the cell lysate thromboplastin suspension produces a clot in a one stage prothrombin time test in about 10 to 15 seconds, with a mean normal prothrombin time of about 11-13 seconds, when added to citrated normal plasma in a volume ratio of about 2:1, such thromboplastin reagent being stable for at least 8 hours at 37.degree. C. and for at least 5 days at 4.degree. C.

Abstract: The present invention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4.degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.

Abstract: The invention relates to an implantation device with which a medicinal implant can be introduced subcutaneously in humans or animals. The device comprises a hollow needle and a mandrel having a chamfered distal end, which precisely coincides with the plane of the chamfered distal end of the hollow needle. The invention also relates to a method for introducing an implant into subcutaneous tissue of humans or animals using the implantation device.

Abstract: A dialysis membrane in the form of a hollow fiber with a continuous internal cavity is made of cellulose acetate or a cellulose acetate derivative. The hollow fiber is made by using a gas to form the internal hollow cavity. A dialysis membrane in the form of a hollow fiber with a continuous hollow cavity may be made in a process using a spinning solution containing an organic carboxylic acid. Modification agents can be added to the solution and the solution extruded through a spinneret suitable for manufacturing hollow fibers, while an internal medium is introduced simultaneously into the internal cavity of the forming hollow fiber. The precipitation of the dialysis membrane thus formed and an ordinary further aftertreatment take place subsequently in a precipitation bath. The hollow fiber is made by using a gas as the internal medium to form the internal cavity.

Abstract: In a method of manufacturing a laminate from at least two layers, a spun bonded nonwoven layer containing thermoplastic endless filaments, as a first layer, and a wetlaid nonwoven layer manufactured by the wet method with short staple fibers made of inorganic fibers (wetlaid nonwoven layer), as the second layer, are bonded together by a joint heat and pressure treatment. To make the wetlaid nonwoven layer, initially short staple fibers, thermoplastic binder, and possible other additives, suspended in water, are applied to a water-permeable substrate that holds back the other components and are dried to form a nonwoven layer. The dried wetlaid nonwoven layer, without further addition of binder, is combined with the spun bonded nonwoven layer before the heat and pressure treatment. A laminate of the invention is composed of at least two layers. A first layer is a spun bonded nonwoven layer containing thermoplastic endless filaments, and a second layer is a wetlaid nonwoven layer containing inorganic fibers.

Abstract: An applicator for introducing a cream-type substance into a woman's vagina is provided with an elongated holder having at its front end a space for accommodating the substance and a passage opening. A rod-shaped piston shuts off the space at the side facing away from the passage opening and can be operated for pressing the substance through the passage opening out of the space. The holder is transparent and is externally slightly curved in order to facilitate its use. The holder is provided on the outside with a projecting stop plate which limits the part of the holder to be inserted into the vagina. At the side of the stop plate facing away from the passage opening the holder is further provided with a handle which is long enough to be gripped with the whole hand. The holder is also provided on the outside, viewed relative to the radius of curvature, with supporting means for supporting the applicator with the passage opening facing upwards.

Abstract: Disclosed is a process of preparing granules involving first preparing a carrier comprising diluent, binder, and optionally a disintegrating agent. In a container separate from said carrier, asteroid, lubricant and, optionally, an antioxidant are dissolved in an, optionally pre-heated, organic solvent. The resulting solution is added to the carrier contained within an, e.g. vacuum mixer, followed by further blending of the mixture. The organic solvent is removed from the mixture. The mixture is blended further to form granules. The process may further include incorporating a flow enhancer such as colloidal silicon dioxide into the granules. A granule for making a pharmaceutical dosage unit is granule characterized in comprising: a) a carrier comprising diluent and binder, and b) a film coating said carrier, said film comprising desogestrel and a lubricant, and has the characteristic of by retaining 90% of the desogestrel at a pressure of 150 mbar and at a temperature of 70.degree. C. over 72 hours.

Abstract: This invention relates to a novel cleaning solution for use particularly with automated analyzers used in clinical laboratories and a method of cleaning a surface with the novel cleaning solution. This solution eliminates problems of cross contamination of samples due to reagent carryover, brought about by the analyzer's probe that dispenses more than one reagent. In particular, this solution resolves carryover problems in coagulation assays performed with automated systems.

Abstract: A cracking catalyst composition comprising a zeolitic, crystalline aluminosilicate, a matrix material and a barium titanium oxide. The catalyst composition is particularly suitable for cracking metal-containing hydrocarbon feedstocks.